Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer

M. Adams, L. Borysiewicz, A. Fiander, S. Man, B. Jasani, H. Navabi, C. Lipetz, A. S. Evans, M. Mason

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Cervical cancer is the second most common cause of cancer death in women worldwide. It is almost invariably associated with infection with human papilloma virus (HPV) particularly types 16 and 18. The ubiquitous expression of E6 and E7 oncogene products has been recognised as an attractive target for CTL-mediated immunotherapy. In-vivo expansion of an HPV oncogene product specific MHC class 1 restricted response has been demonstrated using intradermally administered live vaccinia virus HPV 16 and 18 E6/E7 gene construct (TA-HPV, Cantab Pharmaceuticals). Responses have been seen in 1/3 evaluable patients with advanced cervical cancer, and 3/12 CIN3 volunteers, and in 4/29 patients with early invasive cervical cancer. Rankin et al. Proceedings of 91st AACR Meeting, San Francisco, April 2000. In addition, the adoptive transfer of ex vivo HPV 16 or 18 positive autologous tumour lysate pulsed dendritic cells is currently being tested as an alternative means of expanding HPV specific CTL in advanced cervical cancer patients. So far an HLA-A*O201 restricted CD8 T cell response has been recorded in the single HLA-A*O201 patient whose tumour was shown to be HPV16 positive. It appears therefore feasible to induce HPV specific CTL responses in patients with cervical cancer using several vaccine strategies. However, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy.

Original languageEnglish
Pages (from-to)2549-2556
Number of pages8
JournalVaccine
Volume19
Issue number17-19
DOIs
Publication statusPublished - Mar 21 2001
Externally publishedYes

Fingerprint

Papillomaviridae
papilloma
uterine cervical neoplasms
Papilloma
clinical trials
Vaccines
vaccines
Uterine Cervical Neoplasms
viruses
Human papillomavirus 18
neoplasms
Human papillomavirus 16
immunotherapy
Neoplasms
HLA-A Antigens
Oncogene Proteins
Immunotherapy
Vaccinia virus
dendritic cells
volunteers

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Adams, M., Borysiewicz, L., Fiander, A., Man, S., Jasani, B., Navabi, H., ... Mason, M. (2001). Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine, 19(17-19), 2549-2556. https://doi.org/10.1016/S0264-410X(00)00488-6

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. / Adams, M.; Borysiewicz, L.; Fiander, A.; Man, S.; Jasani, B.; Navabi, H.; Lipetz, C.; Evans, A. S.; Mason, M.

In: Vaccine, Vol. 19, No. 17-19, 21.03.2001, p. 2549-2556.

Research output: Contribution to journalArticle

Adams, M, Borysiewicz, L, Fiander, A, Man, S, Jasani, B, Navabi, H, Lipetz, C, Evans, AS & Mason, M 2001, 'Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer', Vaccine, vol. 19, no. 17-19, pp. 2549-2556. https://doi.org/10.1016/S0264-410X(00)00488-6
Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine. 2001 Mar 21;19(17-19):2549-2556. https://doi.org/10.1016/S0264-410X(00)00488-6
Adams, M. ; Borysiewicz, L. ; Fiander, A. ; Man, S. ; Jasani, B. ; Navabi, H. ; Lipetz, C. ; Evans, A. S. ; Mason, M. / Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. In: Vaccine. 2001 ; Vol. 19, No. 17-19. pp. 2549-2556.
@article{b8f0b33cc465456ea889a42b1154ebb3,
title = "Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer",
abstract = "Cervical cancer is the second most common cause of cancer death in women worldwide. It is almost invariably associated with infection with human papilloma virus (HPV) particularly types 16 and 18. The ubiquitous expression of E6 and E7 oncogene products has been recognised as an attractive target for CTL-mediated immunotherapy. In-vivo expansion of an HPV oncogene product specific MHC class 1 restricted response has been demonstrated using intradermally administered live vaccinia virus HPV 16 and 18 E6/E7 gene construct (TA-HPV, Cantab Pharmaceuticals). Responses have been seen in 1/3 evaluable patients with advanced cervical cancer, and 3/12 CIN3 volunteers, and in 4/29 patients with early invasive cervical cancer. Rankin et al. Proceedings of 91st AACR Meeting, San Francisco, April 2000. In addition, the adoptive transfer of ex vivo HPV 16 or 18 positive autologous tumour lysate pulsed dendritic cells is currently being tested as an alternative means of expanding HPV specific CTL in advanced cervical cancer patients. So far an HLA-A*O201 restricted CD8 T cell response has been recorded in the single HLA-A*O201 patient whose tumour was shown to be HPV16 positive. It appears therefore feasible to induce HPV specific CTL responses in patients with cervical cancer using several vaccine strategies. However, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy.",
author = "M. Adams and L. Borysiewicz and A. Fiander and S. Man and B. Jasani and H. Navabi and C. Lipetz and Evans, {A. S.} and M. Mason",
year = "2001",
month = "3",
day = "21",
doi = "10.1016/S0264-410X(00)00488-6",
language = "English",
volume = "19",
pages = "2549--2556",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "17-19",

}

TY - JOUR

T1 - Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer

AU - Adams, M.

AU - Borysiewicz, L.

AU - Fiander, A.

AU - Man, S.

AU - Jasani, B.

AU - Navabi, H.

AU - Lipetz, C.

AU - Evans, A. S.

AU - Mason, M.

PY - 2001/3/21

Y1 - 2001/3/21

N2 - Cervical cancer is the second most common cause of cancer death in women worldwide. It is almost invariably associated with infection with human papilloma virus (HPV) particularly types 16 and 18. The ubiquitous expression of E6 and E7 oncogene products has been recognised as an attractive target for CTL-mediated immunotherapy. In-vivo expansion of an HPV oncogene product specific MHC class 1 restricted response has been demonstrated using intradermally administered live vaccinia virus HPV 16 and 18 E6/E7 gene construct (TA-HPV, Cantab Pharmaceuticals). Responses have been seen in 1/3 evaluable patients with advanced cervical cancer, and 3/12 CIN3 volunteers, and in 4/29 patients with early invasive cervical cancer. Rankin et al. Proceedings of 91st AACR Meeting, San Francisco, April 2000. In addition, the adoptive transfer of ex vivo HPV 16 or 18 positive autologous tumour lysate pulsed dendritic cells is currently being tested as an alternative means of expanding HPV specific CTL in advanced cervical cancer patients. So far an HLA-A*O201 restricted CD8 T cell response has been recorded in the single HLA-A*O201 patient whose tumour was shown to be HPV16 positive. It appears therefore feasible to induce HPV specific CTL responses in patients with cervical cancer using several vaccine strategies. However, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy.

AB - Cervical cancer is the second most common cause of cancer death in women worldwide. It is almost invariably associated with infection with human papilloma virus (HPV) particularly types 16 and 18. The ubiquitous expression of E6 and E7 oncogene products has been recognised as an attractive target for CTL-mediated immunotherapy. In-vivo expansion of an HPV oncogene product specific MHC class 1 restricted response has been demonstrated using intradermally administered live vaccinia virus HPV 16 and 18 E6/E7 gene construct (TA-HPV, Cantab Pharmaceuticals). Responses have been seen in 1/3 evaluable patients with advanced cervical cancer, and 3/12 CIN3 volunteers, and in 4/29 patients with early invasive cervical cancer. Rankin et al. Proceedings of 91st AACR Meeting, San Francisco, April 2000. In addition, the adoptive transfer of ex vivo HPV 16 or 18 positive autologous tumour lysate pulsed dendritic cells is currently being tested as an alternative means of expanding HPV specific CTL in advanced cervical cancer patients. So far an HLA-A*O201 restricted CD8 T cell response has been recorded in the single HLA-A*O201 patient whose tumour was shown to be HPV16 positive. It appears therefore feasible to induce HPV specific CTL responses in patients with cervical cancer using several vaccine strategies. However, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035925582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035925582&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00488-6

DO - 10.1016/S0264-410X(00)00488-6

M3 - Article

VL - 19

SP - 2549

EP - 2556

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-19

ER -